NEU Neuren Pharmaceuticals Ltd
- 19.020
- -1.250-6.17%
Neuren Pharmaceuticals Ltd News
Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 46%?
These ASX Shares Could Rise 25% to 35%
If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below.
Why Cettire, Neuren, Peter Warren, and Qantas Shares Are Falling Today
The S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to the release of a hotter than expected inflation reading, the benchmark index is down 1.35% to 7,661.5 points.
Neuren Pharmaceuticals Price Target Raised 8% to A$31.29/Share by Petra Capital
Neuren Pharmaceuticals Price Target Raised 8% to A$31.29/Share by Petra Capital
This ASX 200 Stock Can Rocket to a Record High: Broker
The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday.
Neuren Pharmaceuticals Price Target Raised 13% to A$30.00/Share by Wilsons
Neuren Pharmaceuticals Price Target Raised 13% to A$30.00/Share by Wilsons
Guess Which ASX 200 Healthcare Share Just Rocketed 11% on 'groundbreaking Trial'
The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200 healthcare share is leaving those gains wanting.
ASX 200 Healthcare Stock up 40% in 6 Months Halted Ahead of Major Trial Results
Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt before the market open today.
Brokers Name 3 ASX Shares to Buy Now 10 May 2024
It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Why Cettire, De Grey Mining, Life360, and Neuren Shares Are Falling Today
The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points.
Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk
0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not
Neuren Pharmaceuticals Price Target Cut 1.9% to A$26.50/Share by Bell Potter
Neuren Pharmaceuticals Price Target Cut 1.9% to A$26.50/Share by Bell Potter
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,
Why This High-flying ASX 200 Healthcare Stock Just Crashed 11%
It was the ASX 200 healthcare stock of the year in 2023, with its share price catapulting 214% in just 12 months.
Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments
Neuren Pharmaceuticals (ASX:NEU) posted AU$243.1 million in cash and short-term investments as of March 31, down from AU$228.5 million as of Dec. 31, 2023, according to a Wednesday Australian bourse f
Neuren Pharmaceuticals' Medication Secures Priority Review From Health Canada
Neuren Pharmaceuticals' (ASX:NEU) trofinetide medication, designed to treat Rett syndrome, secured a new drug application priority review from Health Canada, according to a Tuesday filing with the Aus
Top ASX Shares to Buy in April 2024
If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index (ASX: XJO) so far in 2024, fear not!
1 Secretly Cheap ASX Stock I'm Buying for the Long Run
Neuren Pharmaceuticals Ltd (ASX: NEU) was the highest climber in the ASX 200 last year, gaining an insane 214% over the calendar year.
$10k of Savings? I'd Buy These ASX 200 Shares to Grow My Money
If you have $10,000 to invest right now, there are some excellent S&P/ASX 200 Index (ASX: XJO) stocks that can grow that money.
Neuren Price Target Cut 7% to A$29.01/Share by Petra Capital
Neuren Price Target Cut 7% to A$29.01/Share by Petra Capital
Analysis
Price Target
No Data
